The Clinical Relevance of Chromogranin A As a Biomarker for Gastroenteropancreatic Neuroendocrine Tumors

Overview

Journal Endocrinol Metab Clin North Am

Publisher Elsevier

Specialty Endocrinology

Date 2011 Feb 26

PMID 21349414

Citations 64

Authors

Ben Lawrence

Bjorn I Gustafsson

Mark Kidd

Marianne Pavel

Bernhard Svejda

Irvin M Modlin

Affiliations

Soon will be listed here.

Abstract

Chromogranin A, although it exhibits limitations, is currently the most useful general tumor biomarker available for use in the diagnosis and management of gastroenteropancreatic neuroendocrine tumors (NETs). The value of the chromogranin A lies in its universal cosecretion by the majority of neuroendocrine cells that persists after malignant transformation. Clinicians aware of the physiologic role of chromogranin A and its secretion in a variety of non-NET-related pathologic conditions can use this protein as a moderately effective tumor biomarker in the management of GEP-NETs.

Citing Articles

[Clinical significance of neuroendocrine tumors : Incidence, symptoms, diagnosis, stage, and prognostic factors and their influence on disease management].

Hartrampf P, Serfling S, Higuchi T, Bojunga J, Weich A, Werner R Radiologie (Heidelb). 2024; 64(7):536-545.

PMID: 38777918 DOI: 10.1007/s00117-024-01315-y.

Predictive Factors of Response to Streptozotocin in Neuroendocrine Pancreatic Neoplasms.

Fanciulli G, La Salvia A, Di Molfetta S, Cannavale G, Puliani G, Verrico M J Clin Med. 2023; 12(24).

PMID: 38137624 PMC: 10743702. DOI: 10.3390/jcm12247557.

The differentially expressed gene signatures of the Cullin 3-RING ubiquitin ligases in neuroendocrine cancer.

Park J, Kim D, Kim J, Jo J, Kim Y, Jung D Biochem Biophys Res Commun. 2022; 636(Pt 2):71-78.

PMID: 36368157 PMC: 9671844. DOI: 10.1016/j.bbrc.2022.10.108.

miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2.

Kooblall K, Stokes V, Shariq O, English K, Stevenson M, Broxholme J Endocr Relat Cancer. 2022; 29(10):557-568.

PMID: 35900839 PMC: 9422251. DOI: 10.1530/ERC-22-0045.

Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy.

Capdevila J, Grande E, Garcia-Carbonero R, Simo M, Del Olmo-Garcia M, Jimenez-Fonseca P Oncologist. 2022; 27(4):e328-e339.

PMID: 35380724 PMC: 8982404. DOI: 10.1093/oncolo/oyab041.